Budget 2023Budget 2023


  • Tata AIA Life Insurance
  • Hafele
  • Motilal Oswal
  • SMC Global Securities Limited
Upcoming Event : LeapToUnicorn - mentoring, networking and fundraising for startups. Register now
Budget 2023
Budget 2023

Supreme Court sets aside Indoco’s request to lift injunction on launch of generic apixaban

Apex court dismisses Indoco’s petition to lift the stay on producing copycat versions of Bristol Myers Squibb’s bestselling anticoagulant medication

July 01, 2021 / 03:03 PM IST
Eris Lifesciences Ltd.

Eris Lifesciences Ltd.

  • bselive
  • nselive
Todays L/H

Indoco Remedies, which is trying to launch a generic version of Bristol Myers Squibb’s top-selling patented anticoagulant medication Eliquis (apixaban), received a setback when the Supreme Court set aside its request to lift the stay by the Delhi High Court on producing the copycat version.

“We are not inclined to interfere with the impugned judgment and the order passed by the high court. The special leave petition is, accordingly, dismissed,” the Supreme Court said in its order in May. Indoco had filed a special leave petition in the apex court seeking to lift the injunction on the launch of apixaban.

Bristol Myers obtained the injunction from the Delhi High Court in December 2019, restraining Indoco, Emcure Pharmaceuticals, Torrent Pharmaceuticals, Cipla and Alkem Laboratories from launching generic versions of the drug, which it claims is patented till September 2022. The drug was granted a patent in 2011.

Bristol Myers and its partner Pfizer sell the drug that’s used in the prevention and treatment of blood clots under the brand Eliquis.